{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&hansardHeading=Medical+Treatments", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&hansardHeading=Medical+Treatments", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&_metadata=all&hansardHeading=Medical+Treatments", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&_page=0&hansardHeading=Medical+Treatments", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&hansardHeading=Medical+Treatments", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&hansardHeading=Medical+Treatments", "items" : [{"_about" : "http://data.parliament.uk/resources/1653015", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1653015/answer", "answerText" : {"_value" : "<p>Marketing Authorisation Holders (MAHs) are encouraged to use the national Key Performance Indicators (KPIs) published in the Royal Pharmaceutical Homecare Services Handbook 2014 in their contracts with homecare providers. MAHs may also use additional or alternative specific KPIs where they consider this necessary. Neither NHS England nor National Health Service trusts are directly party to those contracts between MAHs and homecare providers, and therefore do not have visibility of the KPIs agreed in each case.<\/p><p>The treatment choice is determined by the clinician in the hospital trust in conversation with the patient, based on the best available evidence and cost-effectiveness aligned to national and local guidance where available. The homecare medicines service provider is contracted to undertake supply and delivery, and administration in some cases. The homecare medicines service provider does not determine the clinical pathway.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Markham"}
        , "dateOfAnswer" : {"_value" : "2023-07-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-07-26T13:33:48.307Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-07-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask His Majesty's Government whether Market Authorisation Holders set different (1) Key Performance Indicator measurements, and (2) clinical pathways, for the same therapy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/497", "label" : {"_value" : "Biography information for Lord Blencathra"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Blencathra"}
      ], "uin" : "HL9314"}
    , {"_about" : "http://data.parliament.uk/resources/1642808", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1642808/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses in the development of its guidance, including the discount rate, taking into account its responsibilities under Managing Public Money.<\/p><p>NICE concluded a comprehensive review of its methods and processes in 2022, including consideration of the discount rate. Following public consultation, NICE concluded that it was appropriate to maintain the existing rate of 3.5% due to policy and fiscal implications and interdependencies beyond the scope of the review. The Department and HM Treasury were engaged throughout the review.<\/p><p>NICE is introducing a new modular approach for further methods updates, where it will work with its system partners on the methodological priorities for the healthcare system.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Markham"}
        , "dateOfAnswer" : {"_value" : "2023-06-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL8290"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-06-22T15:59:34.74Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-06-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask His Majesty's Government, further to the remarks by Lord Markham on 25 May (HL Deb col 1032), whether the National Institute for Health and Care Excellence is currently considering changing the reference case discount rate for costs and health effects that is applied to new health technologies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2024", "label" : {"_value" : "Biography information for Lord Hunt of Kings Heath"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Hunt of Kings Heath"}
      ], "uin" : "HL8289"}
    , {"_about" : "http://data.parliament.uk/resources/1642809", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1642809/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses in the development of its guidance, including the discount rate, taking into account its responsibilities under Managing Public Money.<\/p><p>NICE concluded a comprehensive review of its methods and processes in 2022, including consideration of the discount rate. Following public consultation, NICE concluded that it was appropriate to maintain the existing rate of 3.5% due to policy and fiscal implications and interdependencies beyond the scope of the review. The Department and HM Treasury were engaged throughout the review.<\/p><p>NICE is introducing a new modular approach for further methods updates, where it will work with its system partners on the methodological priorities for the healthcare system.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Markham"}
        , "dateOfAnswer" : {"_value" : "2023-06-22", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL8289"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-06-22T15:59:34.793Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-06-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask His Majesty's Government, further to the remarks by Lord Markham on 25 May (HL Deb col 1032), whether decisions about changes to the reference case discount rate applied to new technologies for costs and health effects are a matter solely for the National Institute for Health and Care Excellence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2024", "label" : {"_value" : "Biography information for Lord Hunt of Kings Heath"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Hunt of Kings Heath"}
      ], "uin" : "HL8290"}
    , {"_about" : "http://data.parliament.uk/resources/1579865", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1579865/answer", "answerText" : {"_value" : "<p>The Department wants patients to benefit from access to effective new treatments at a price that represents value and is fair to all parties. The National Institute for Health and Care Excellence (NICE) has been able to recommend over 95% of the combination therapies on which it published technology appraisal guidance between 2017 and 2022. NICE is developing a modular approach to its methods and process updates and potential topics will be considered by NICE taking into account all relevant factors.<\/p><p>NHS England\u2019s Commercial Framework for New Medicines recognises that realising the full potential health benefits from combination drug therapies can be challenging given the requirement for commercial confidentiality and the need to maintain competition.<\/p><p>Alongside NICE, NHS England has been supporting the Association of the British Pharmaceutical Industry (ABPI) efforts to find solutions to enable companies to engage with one another where health-improving combination therapies face challenges coming to market.<\/p><p>In the United Kingdom, the Competition and Markets Authority represents the sole competent authority, and the commercial aspects of bringing combination therapies to the market must be compliant with relevant legislation.<\/p><p>There are currently no plans to establish a task and finish group.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-01-30", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "129956"}
        , {"_value" : "129957"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-01-30T17:10:30.027Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-01-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether it is his policy to work with (a) patient groups, (b) industry stakeholders and (c) other relevant parties on finding solutions to the challenges of patient access to combination therapy treatments, including (i) a lack of framework for multi-indication pricing, (ii) rigid cost-effectiveness frameworks and (iii) legal barriers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "129952"}
    , {"_about" : "http://data.parliament.uk/resources/1579866", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1579866/answer", "answerText" : {"_value" : "<p>The Department is considering how a successor to the voluntary scheme for branded medicines pricing and access should operate from 2024 onwards and will work with industry to agree a mutually beneficial successor that that supports better patient outcomes, ensuring the sustainability of National Health Service spend on branded medicines and enables a strong United Kingdom life sciences industry.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-01-30", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-01-30T17:02:55.373Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-01-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether policies to improve patient access to combination therapies will be considered by his Department in upcoming negotiations for the 2024 Voluntary Scheme for Branded Medicines Pricing and Access.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "129953"}
    , {"_about" : "http://data.parliament.uk/resources/1579868", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1579868/answer", "answerText" : {"_value" : "<p>Between 1 January 2017 and 31 December 2022, 20% of appraisals of combination therapies undertaken by the National Institute for Health and Care Excellence (NICE) were terminated due to the company not making an evidence submission to NICE.<\/p><p>Of the technologies appraised by NICE, 4% were not recommended, 31% were recommended for routine commissioning, 52% were optimised recommendations and 12% were recommended or optimised for use within the Cancer Drugs Fund.<\/p><p>No applications were recommended for the Innovative Medicines fund.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-02-02", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-02-02T15:21:00.617Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-01-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what percentage of health technology appraisals conducted by NICE for therapies in combination have resulted in (a) termination, (b) a negative recommendation, (c) an optimised recommendation, (d) a positive recommendation or (e) a recommendation for use within the Cancer Drugs Fund or Innovative Medicines Fund.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "129955"}
    , {"_about" : "http://data.parliament.uk/resources/1551539", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1551539/answer", "answerText" : {"_value" : "<p>There have been no recent discussions. The National Institute for Health and Care Excellence (NICE) concluded a review of its methods and processes for health technology evaluation, including consideration of the discount rate and published its updated manual on 31 January 2022. NICE\u2019s final consultation on proposed changes closed on 13 October 2021. NICE concluded that while there was some evidence to support a change to the reference case discount rate, it was appropriate to maintain the existing rate of 3.5% due to policy and fiscal implications and interdependencies beyond the scope of the review.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2022-12-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-12-22T10:56:17.37Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-12-14", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has held recent discussions with the National Institute for Health and Care Excellence on changing the discount rate; what his planned timetable is for this work; and whether it will be subject to formal public consultation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "110708"}
    , {"_about" : "http://data.parliament.uk/resources/1523380", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1523380/answer", "answerText" : {"_value" : "<p>We are supporting companies to develop and deploy health technologies, including the Data for Research and Development Programme to make research-ready data available to innovators in a streamlined and secure way. The Artificial Intelligence in Health and Care Award provides funding and practical support to the most promising AI technologies, including 30 which are being deployed for testing and the small Business Research Initiative Healthcare Award programme supports innovators and entrepreneurs in health and social care.<\/p><p>\u2018A plan for digital health and social care\u2019 published in June 2022 also set out how we are developing and embedding technology and digital solutions in the National Health Service.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2022-11-01", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-11-01T11:54:10.963Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-10-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will take steps with Cabinet colleagues to support companies to (a) develop and (b) deploy life-saving health technology solutions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "65781"}
    , {"_about" : "http://data.parliament.uk/resources/1485909", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1485909/answer", "answerText" : {"_value" : "<p>The agenda has been finalised and made available to relevant stakeholders.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Kamall"}
        , "dateOfAnswer" : {"_value" : "2022-07-18", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL1396"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-07-18T15:01:12.337Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-07-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 June (HL645), whether an agenda for NHS England's Clinical Priorities Advisory Group's next meeting has been finalised; and if so, when it will be shared with relevant stakeholders.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
      ], "uin" : "HL1440"}
    , {"_about" : "http://data.parliament.uk/resources/1485232", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1485232/answer", "answerText" : {"_value" : "<p>The agenda has been finalised and made available to relevant stakeholders.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Kamall"}
        , "dateOfAnswer" : {"_value" : "2022-07-18", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL1440"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-07-18T15:01:12.287Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-06-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 June (HL645), whether an agenda for NHS England's Clinical Priorities Advisory Group's next meeting has been finalised; and if so, when the agenda will be shared with stakeholders.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
      ], "uin" : "HL1396"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&_page=1&hansardHeading=Medical+Treatments", "page" : 0, "startIndex" : 1, "totalResults" : 64, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}